News
-
-
REGULATED PRESS RELEASE
bioMérieux receives Dual 510(k) Clearance and CLIA Waiver from the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel to Advance Women’s Health with Rapid Molecular Diagnostics
bioMérieux receives Dual 510(k) Clearance and CLIA Waiver from the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel, advancing women’s health with rapid molecular diagnostics -
-
REGULATED PRESS RELEASE
WHO Grants Emergency Use Listing for BIOFIRE® Global Fever Special Pathogens Panel, Expanding Access to Differential Diagnostics for the Ebola Response
WHO grants Emergency Use Listing for BIOFIRE® Global Fever Special Pathogens Panel, enhancing Ebola response with fast, accurate diagnostics from bioMérieux. Panel detects 16 pathogens in 1-hour test, aiding outbreak containment and future preparedness -
-
-
REGULATED PRESS RELEASE
bioMérieux Launches SPINCHIP® hs-cTnl, a Major Innovation for the Measurement of High-Sensitivity Cardiac Troponin I and Faster Management of Cardiac Emergencies
bioMérieux launches SPINCHIP® hs-cTnl, a rapid diagnostic solution for high-sensitivity cardiac troponin I measurement, enabling faster triage of adult patients with suspected acute myocardial infarction -
-
REGULATED PRESS RELEASE
bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
bioMérieux achieves IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, including MERS-CoV. The certification reinforces the company's commitment to providing comprehensive diagnostic solutions for infectious diseases -
